Skip to main content

International Journal of Phytomedicine and Phytotherapy

Table 3 Treatment indications (> 3%) (Safety Set)

From: A non-interventional, prospective, multicenter study for evaluation of the use of the herbal medicinal product Canephron® N in the pediatric outpatient population in Russia

  HMP form
Indication Total Oral solution Tablets
System Organ Class / Preferred Term (N = 634) (N = 421) (N = 213)
Infections and infestation 475 (74.9%) 326 (77.4%) 149 (70.0%)
 Urinary tract infection 216 (34.1%) 171 (40.6%) 45 (21.1%)
 Pyelonephritis chronica 80 (12.6%) 40 (9.5%) 40 (18.8%)
 Cystitis 72 (11.4%) 39 (9.3%) 33 (15.5%)
 Pyelonephritisa 71 (11.2%) 50 (11.9%) 21 (9.9%)
 Pyelonephritis acutea 39 (6.2%) 29 (6.9%) 10 (4.7%)
Renal and urinary disorders 225 (35.5%) 136 (32.3%) 89 (41.8%)
 Hyperoxaluria 106 (16.7%) 73 (17.3%) 33 (15.5%)
 Hypercalciuria 31 (4.9%) 20 (4.8%) 11 (5.2%)
 Calculus urinary 23 (3.6%) 12 (2.9%) 11 (5.2%)
 Haematuria 23 (3.6%) 15 (3.6%) 8 (3.8%)
  1. aPyelonephritis was classified in case it was not further specified by the physician whether acute or chronic pyelonephritis was present